Plasma Fractionation Market Synopsis

Plasma Fractionation Market Size Was Valued at USD  38.24 Billion in 2023, and is Projected to Reach USD  78.37 Billion by 2032, Growing at a CAGR of 8.30% From 2024-2032.

The global industry that separates and purifies plasma release issues, including immunoglobulins, coagulation factors, albumens and protease inhibitors is referred to as Plasma Fractionation Market. These parts help manage many conditions such as deficiency in immunity, coagulopathies, and autoimmune disorders. It in a way refers to the plasma collection which is a process of blood plasma extraction that precedes HIV infected plasma collection, plasma fractionation and finally the manufacture of plasma derived products. The growth rate in this market is closely tied with factors such as increased prevalence of chronic diseases, improvements of the healthcare infrastructure and the requirement of immunoglobulins with other plasma by products.

• This market indicates the Plasma Fractionation Market that holds the gateway into the demand of plasma derived medicinal products those are used in various health ailments such as immunodeficiency diseases, hemophilia and other bleeding disorders.. Fractionation of plasma refers to the separation of plasma into it compositions like the albumin, the immunoglobulins and the clotting factors. The market for plasma fractionation has remained progressive as we find increased prevalence of chronic diseases, increased geriatric population, enhanced fractional technologies, and effective awareness for therapeutic uses of plasma products. Hence, increasing Incarnation of plasma-derived products for the treatment of rare diseases has also driven the market.
• Another growth stimulating trend in the Plasma Fractionation Market involves proliferation of the immunoglobulins or, in other words, the intravenous immunoglobulins for treatment of certain conditions like immunodeficiencies, hemophilia, among other bleeding ailments.. Plasma fractionation refers to the sub dividing of plasma in to its various category these include albumin, immunoglobulins, and clotting factors. The Plasma Fractionation Market has remained on the climb globally due to factors such as: Increasing chronic diseases; Increasing geriatric population; Enhancements in fractionation technology; Awareness regarding therapeutic uses of plasma-derived products. Rise in Adoption of plasma-derived products especially for managing rare disease has also boosted market growt.
• The increased focus on Immunoglobulins, or more specifically, Intravenous immunoglobulins is one of the biggest factors leading to this growth of Plasma Fractionation Market. IVIG is used for any diseases, which is associated with immunologic pathology like PID’s, autoimmune disorders and many neurological diseases. Immunocancers and autoimmune diseases are diseases that are on the rise and are using immunoglobulins in different therapeutic segments that have helped to boost the market. Besides, the availability of plasma-derived therapies in developing countries due to enhancement in their health care infrastructure and escalating government-sponsored programs created more opportunities. They also have remained committed to spending large amounts of money on research and development programs to look for ways to advance and optimize plasma fractionation processes, to advance the quality of the PD products.
• There has also been information that in the recent years sever change has been come across in the plasma collection and processing technologies that added up the advantage in fractionation and treatment of deficiency diseases like immunodeficiencies, hemophilia and other bleeding disorders. Plasma fractionation is the separation of plasma into its various parts include albumin, immunoglobulins and clotting factors. The plasma fractionation market has been growing over the years globally due to potential applications of plasma derived products, increase in rate of chronic diseases, geriatric population, advancement of fractional techniques and awareness of therapeutic benefits achievable with plasma fractionation. Increasing demand for plasma-derived products also serve as an important treatment for rare diseases also acts as a factor that has also promoted the expansion of the market.
• A major growth factor driving the growth of the Plasma Fractionation Market is the rising demand for immunoglobulins, or more precisely, intravenous immunoglobulins. IVIG treats a wide spectrum of diseases-from primary immunodeficiency diseases and autoimmune diseases to neurological disorders. Growing incidence of these diseases together with increasing applications of immunoglobulins in therapeutic areas has powered the expansion of the market. In addition, new business opportunities were created through the increase in the use of plasma derived therapies in developmental countries due to the enhanced health care structures as well as prevalent government corollary. Business also remain committed to carrying out research and development exercises to find better ways of to plasma fractionation, increasing quality and safety of plasmal products.
• The market has also witnessed a number of improvements in plasma collection and processing technologies during recent years that have optimized the fractionation process. Yields in plasma-derived products have subjected enhancements in filtration, chromatography and other methodologies of purification. The rising use of recombinant DNA technology within the CMP manufacture of the clotting factors for instance Factor VIII and Factor IX indicates a shift to the new treatment model for patients with hemophilia. These are minimizing the likelihood of viral infection and improving the safety and effectiveness of plasma derived products thus promoting its use.
• The future of the Plasma Fractionation Market seems exciting with continuous technology development and an increasing focus on personalized medicine, which is foreseen to open additional growth opportunities. Some of these are the development of the latters that have an extended half-life and therefore require administration for a shorter time. In addition, it is expected that new fields of application for plasma derived products for oncology and infectious diseases can create new horizons for the market. It is also relevant that these challenges-cost for one, compliance and safety for the other-are self-solved by the stakeholders so as to optimize market possibilities and open up more and more access to such lifesaving therapies.

Plasma Fractionation Market Trend Analysis

Rising Demand for Immunoglobulins

• The immunoglobulins demand is one of the ways that have significantly contributed towards the growth of the plasma fractionation market.. Immunoglobulins or antibodies found their application in different types of immunological and hematological diseases among them primary and secondary immunodeficiency, autoimmune and inflammatory diseases. Such diseases have also gone up due to population aging and thus leading to higher demand globally. These have further helped in the market growth as Plasma fractionation technologies have improved and yielded better immunoglobulin results in efficiency. Secondly the new and improved forms of immunoglobulin products such as the subcutaneous immunoglobulins widened the market as it is easier to administer.Furthermore, a number of the main stakeholders are gradually entering into strategic partnerships, mergers or acquisitions – all of which are helping support these new advancements in the plasma derived therapies. form a basis for various kinds of immunological and hematological disorders, including primary and secondary immunodeficiency diseases, autoimmune disorders, and inflammatory conditions. The increase in such diseases has, in turn, resulted in increased demand due to an aging population worldwide. Along with better plasma fractionation techniques, these enhanced efficiency and better yields in immunoglobulin production, therefore helped in the market growth. Secondly, the availability of newer and more innovative kinds of immunoglobulin products, like subcutaneous immunoglobulins, also helped expand the market because it offers greater convenience in administration.
• Further, some key players are increasingly engaging in strategic collaborations, mergers, and acquisitions, thereby facilitating these advanced developments within plasma-derived therapies. There are plenty of companies investing in research and development studies so as to improve safety and efficacy of immunoglobulins and to cover the increasing demand. On a geographical perspective, North America and Europe hold the largest share of the immunoglobulin market due to sound healthcare structure, better reimbursement policies, and increased awareness associated with immunoglobulin products. Asia Pacific region has however shownrsquos potential as a market due to rising healthcare spending across the globe, a growing population of patients especially where there is more awareness on plasma fractionation and immunoglobulin therapies. Overall, these aspects collectively will probably shape the perceived growth potential of the plasma fractionation market across the forecast years.

Advancements in Fractionation Technology

•  New frontiers in fractionation are as follow: They have turned the plasma fractionation market into one that is significantly more efficient and less costly in terms of production of therapeutic proteins and clotting factors.. Sophisticated techniques of fractionation like new improved latex bead column chromatography methods and new technologies in filtration have boosted up the yield and purity of the plasma derived products. Advanced technology such as continuous chromatography and enhanced fractionation has provided means for lower production time and costs, so as to meet the increasing market demand. Also, improvement in analytical technologies as well as quality control has enhanced the safety and reliability of plasma derived therapies.ffective production of therapeutic proteins and clotting factors. Modern fractionation techniques, such as improved chromatography methods and advanced filtration technologies, have enhanced the separation and purification processes, resulting in higher yields and purity of plasma-derived products. Innovations like continuous chromatography and automation in fractionation processes have reduced production times and operational costs, enabling manufacturers to meet growing demand with greater efficiency.
• Additionally, advancements in analytical technologies and quality control methods have bolstered the safety and efficacy of plasma-derived therapies. There are better ways at detecting and even monitoring the prospects for contamination or any difference in quality of the products. These technological advances guarantee the highest level of protection as well as offer the foundation for enhancing new and advanced forms of specialized treatment, which expands the choices available to patients suffering from atypical and complicated diseases. In this dynamic market, therefore, further research and development in fractionation technology are likely to push the pace of innovation and improvement in plasma-based therapies.

Plasma Fractionation Market Segment Analysis:

Plasma Fractionation Market Segmented based on  Product Type, Application, and End User.

By   Product Type,     Immunoglobulins segment is expected to dominate the market during the forecast period

• By type, the markets for plasma fractionation have been segmented into several significant types, every one of which fulfills distinct therapeutic roles.. The first large segment is formed by immunoglobulins which have rather a wide spectrum of efficacy in improving immunity and are therefore believed to be essential for the treatment of numerous autoimmune diseases and conditions caused by immunodeficiency. Concentrates of coagulation factors are vital in the management of bleeding disorders through administering clotting factors through blood transfusion to patient suffering from hemophilia. Other products include albumin which is used to treat diseases such as liver cirrhosis and also burn injury because it increases blood volume and pressure within normal range. Protease inhibitors used to inhibit proteolysis make for many treatments of diseases resulted from protein decomposition. Others: Included in this category are several other plasma derived products that are applied in treatments typical of the diversified roles of plasma fractionation in medicine.• Factors affecting the market of these product types include a growing pool of chronic diseases globally, improved plasma fractionation, and the growing need for personalized medicine. broad-spectrum immunity-enhancing properties and are thus considered indispensable in treating a variety of autoimmune diseases and conditions of immunodeficiency. Concentrates of coagulation factors are essential for the treatment of bleeding disorders, including hemophilia, by infusing blood with the deficient clotting factors. Other important products include albumin, which is utilized in the treatment of diseases like liver cirrhosis and also burn injuries because it maintains the volume and pressure of blood within normal ranges. Protease inhibitors, applied to prevent proteolysis, form the basis of many treatments for diseases caused by protein degradation. Others: This category includes several miscellaneous plasma-derived products used in treatments indicative of the broad range of applications of plasma fractionation in medicine.
• The market dynamics for these product types are influenced by factors such as rising prevalence of chronic diseases, advancements in plasma fractionation technologies, and increasing demand for personalized medicine. However, growth of immunoglobulin therapies is more or less proportional to the existing patient pool of autoimmune diseases and other forms of immunodeficiency. Coagulation factor concentrates in its turn expects higher demand due to the ongoing development of hemophilia treatment and the enhancement of a knowledge of blood disorders. Albumin application has been originally based on its critical importance to severe conditions management while protease inhibitors face growing interest in particular therapeutic fields. Altogether, the further evolution and future outlook in all the segments of the plasma fractionation market indicates the efforts of integration of innovation, therapeutic requirements and, of course, patient category.

By Application , Hematology segment held the largest share in 2023

• The plasma fractionation market is classified, based on application into neurological disorders, immunology, hematology, critical care, and others.. In neurology, the plasma derived products are used mainly in cases of neurological diseases, for instance multiple sclerosis where immunoglobulins change the immune reaction. Immunology contributes considerably to plasma fractionation for it provides the primary source of immunoglobulins and coagulation factors in immuno deficient and autoimmune diseases afflicted individuals. Immunoglobulins and other plasma derived therapeutics remain also central in supporting immune functions and treating autoimmune diseases, all of which explains the demand in this field. In the production of clotting factors required for the patient suffering from hemophilia and other related diseases associated with blood clotting plasma fractionation is important in the hematology industry.help with neurological disorders, such as multiple sclerosis, wherein immunoglobulins modify the immune response. Plasma fractionation plays a vital role in the immunology segment due to the prime supply of essential immunoglobulins and clotting factors in patients suffering from immune deficiencies and autoimmune disorders. Plasma-derived therapies, including immunoglobulins, are further critical in enhancing immune functions and managing autoimmune diseases, hence the demand in the sector.
• In the field of hematology, plasma fractionation is important in the manufacture of clotting factors used for patients with hemophilia and other disorders affecting blood coagulation. Plasma products used to the critical care segment assist indications that include severe trauma, shock, and other life-threatening indications wherein rapid component replacement is done. Others include the small treatment that targets the genetic disorders and other diseases that are seen to be rare hence they contribute to market growth. In one way or the other, these various disorders make plasma fractionation important for managing many diseases, and thus have become an essential component of contemporary medicine.

Plasma Fractionation Market Regional Insights:

Asia Pacific is Expected to Dominate the Market Over the Forecast period

• During the given forecast period, Asia Pacific is anticipated to exhibit the maximum growth in plasma fractionation due to its growing healthcare investment, and because the number of patients suffering from chronic diseases along with awareness among the public about plasma therapies has risen.. There is a significant investment by Asian countries particularly China, India and Japan in their healthcare systems, including research in plasma that will not only increase plasma availability but also enhance the quality of plasma products. New healthcare facilities and the development of technologies are being a driving force in the growth of the plasma fractionation market in this region. Furthermore, the increasing health awareness and the demand for immunoglobulins and clotting factors & other plasma derivatives products also aids the growth of the blood plasma collection & processing market in Asia Pacific in the future the government support towards blood plasma collection and processing market is also a key factor for the growth of blood plasma collection & processing market in Asia Pacific. A favourable policy environment and partnerships between market leaders give other players in the Asia Pacific plasma fractionation market additional growth opportunities.h an increase in the prevalence of chronic diseases and awareness about plasma-derived therapies. Countries such as China, India, and Japan are investing majorly in healthcare infrastructure along with research, which will improve availability and the quality of plasma products. The expansion of healthcare facilities and advancements in technology are contributing to the growth of the plasma fractionation market in this region. Additionally, the rising demand for immunoglobulins, clotting factors, and other plasma-derived products, coupled with increasing government initiatives to support the blood plasma collection and processing industry, further bolsters the market's expansion in Asia Pacific.
• A favorable regulatory environment and strategic collaborations between key players further support the growth of the Asia Pacific plasma fractionation market. Establishments are choosing to form alliances with local companies in order to bring their products into this expanding market and strengthen distribution channels. More availability of Plasma donation centers, and the development of the fractionation technologies are the factors that will help grow this market. Furthermore, rising incidences of diseases such as hemophilia and autoimmune diseases require plasma derived therapeutic products and will increase the demand. For these reasons, Asia Pacific will be a prominent player in the global plasma fractionation market due to its population count, and enhancing healthcare sector.

Active Key Players in the Plasma Fractionation Market

• Grifols S.A. (Spain)
• CSL Behring (Australia)
• Octapharma AG (Switzerland)
• Takeda Pharmaceutical Company Limited (Japan)
• Biotest AG (Germany)
• Kedrion Biopharma Inc. (Italy)
• China Biologic Products Holdings, Inc. (China)
• LFB Group (France)
• Sanquin Plasma Products (Netherlands)
• Emergent BioSolutions Inc. (United States)
• Others Key Player

Key Industry Developments in the Plasma Fractionation Market

• December 2023 – Octapharma AG received extended approval from the U.S. FDA for its plasma-based product, wilate (von Willebrand Factor/Coagulation Factor VIII Complex). The new extended approval label comprises routine prophylaxis aimed to reduce the frequency of bleeding episodes in adults and children aged six years and above.
• November 2023 – Grifols, S.A. received the U.S. FDA approval for its new immunoglobulin (Ig) purification and filling facility in North Carolina. Through this facility, the company was able to manufacture an additional 16 million grams of plasma therapy annually.
• March 2023 – Grifols, S.A. established a manufacturing facility in Marburg, Germany, with an expanded manufacturing capacity for human plasma therapies.
• March 2023 – Takeda Pharmaceutical Company Limited invested USD 764.6 million to build a new plasma-derived therapy production site in Osaka, Japan. The facility will be operational by 2030 and will expand the company’s manufacturing capacity in Japan fivefold.
• January 2022 – Octapharma AG announced that the European Union (EU) expanded the indication for cutaquig, a human immunoglobulin administered subcutaneously. The expansion would provide more flexible treatment options to patients with acquired immune deficiencies.

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Plasma Fractionation Market by Product Type
 4.1 Plasma Fractionation Market Snapshot and Growth Engine
 4.2 Plasma Fractionation Market Overview
 4.3 Immunoglobulins
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Immunoglobulins: Geographic Segmentation Analysis
 4.4 Coagulation Factor Concentrates
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Coagulation Factor Concentrates: Geographic Segmentation Analysis
 4.5 Albumi
  4.5.1 Introduction and Market Overview
  4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.5.3 Key Market Trends, Growth Factors and Opportunities
  4.5.4 Albumi: Geographic Segmentation Analysis
 4.6 Protease Inhibitors
  4.6.1 Introduction and Market Overview
  4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.6.3 Key Market Trends, Growth Factors and Opportunities
  4.6.4 Protease Inhibitors : Geographic Segmentation Analysis
 4.7 Others
  4.7.1 Introduction and Market Overview
  4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.7.3 Key Market Trends, Growth Factors and Opportunities
  4.7.4 Others: Geographic Segmentation Analysis

Chapter 5: Plasma Fractionation Market by Application
 5.1 Plasma Fractionation Market Snapshot and Growth Engine
 5.2 Plasma Fractionation Market Overview
 5.3 Neurology
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Neurology: Geographic Segmentation Analysis
 5.4 Immunology
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Immunology: Geographic Segmentation Analysis
 5.5 Hematology
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Hematology: Geographic Segmentation Analysis
 5.6 Critical Care
  5.6.1 Introduction and Market Overview
  5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.6.3 Key Market Trends, Growth Factors and Opportunities
  5.6.4 Critical Care: Geographic Segmentation Analysis
 5.7 Others
  5.7.1 Introduction and Market Overview
  5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.7.3 Key Market Trends, Growth Factors and Opportunities
  5.7.4 Others: Geographic Segmentation Analysis

Chapter 6: Plasma Fractionation Market by End-User
 6.1 Plasma Fractionation Market Snapshot and Growth Engine
 6.2 Plasma Fractionation Market Overview
 6.3 Hospitals & Clinics
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Hospitals & Clinics: Geographic Segmentation Analysis
 6.4 Research Laboratories
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Research Laboratories: Geographic Segmentation Analysis
 6.5 Academic Institutions
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Academic Institutions: Geographic Segmentation Analysis
 6.6 Biopharmaceutical Companies
  6.6.1 Introduction and Market Overview
  6.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.6.3 Key Market Trends, Growth Factors and Opportunities
  6.6.4 Biopharmaceutical Companies: Geographic Segmentation Analysis

Chapter 7: Company Profiles and Competitive Analysis
 7.1 Competitive Landscape
  7.1.1 Competitive Benchmarking
  7.1.2 Plasma Fractionation Market Share by Manufacturer (2023)
  7.1.3 Industry BCG Matrix
  7.1.4 Heat Map Analysis
  7.1.5 Mergers and Acquisitions
  
 7.2 GRIFOLS
  7.2.1 Company Overview
  7.2.2 Key Executives
  7.2.3 Company Snapshot
  7.2.4 Role of the Company in the Market
  7.2.5 Sustainability and Social Responsibility
  7.2.6 Operating Business Segments
  7.2.7 Product Portfolio
  7.2.8 Business Performance
  7.2.9 Key Strategic Moves and Recent Developments
  7.2.10 SWOT Analysis
 7.3 CSL BEHRING
 7.4 OCTAPHARMA
 7.5 TAKEDA
 7.6 BIOTEST
 7.7 KEDRION BIOPHARMA
 7.8 CHINA BIOLOGIC PRODUCTS HOLDINGS
 7.9 LFB
 7.10 SANQUIN PLASMA PRODUCTS
 7.11 EMERGENT BIOSOLUTIONS
 7.12 OTHERS KEY PLAYER

Chapter 8: Global Plasma Fractionation Market By Region
 8.1 Overview
 8.2. North America Plasma Fractionation Market
  8.2.1 Key Market Trends, Growth Factors and Opportunities
  8.2.2 Top Key Companies
  8.2.3 Historic and Forecasted Market Size by Segments
  8.2.4 Historic and Forecasted Market Size By Product Type
  8.2.4.1 Immunoglobulins
  8.2.4.2 Coagulation Factor Concentrates
  8.2.4.3 Albumi
  8.2.4.4 Protease Inhibitors
  8.2.4.5 Others
  8.2.5 Historic and Forecasted Market Size By Application
  8.2.5.1 Neurology
  8.2.5.2 Immunology
  8.2.5.3 Hematology
  8.2.5.4 Critical Care
  8.2.5.5 Others
  8.2.6 Historic and Forecasted Market Size By End-User
  8.2.6.1 Hospitals & Clinics
  8.2.6.2 Research Laboratories
  8.2.6.3 Academic Institutions
  8.2.6.4 Biopharmaceutical Companies
  8.2.7 Historic and Forecast Market Size by Country
  8.2.7.1 US
  8.2.7.2 Canada
  8.2.7.3 Mexico
 8.3. Eastern Europe Plasma Fractionation Market
  8.3.1 Key Market Trends, Growth Factors and Opportunities
  8.3.2 Top Key Companies
  8.3.3 Historic and Forecasted Market Size by Segments
  8.3.4 Historic and Forecasted Market Size By Product Type
  8.3.4.1 Immunoglobulins
  8.3.4.2 Coagulation Factor Concentrates
  8.3.4.3 Albumi
  8.3.4.4 Protease Inhibitors
  8.3.4.5 Others
  8.3.5 Historic and Forecasted Market Size By Application
  8.3.5.1 Neurology
  8.3.5.2 Immunology
  8.3.5.3 Hematology
  8.3.5.4 Critical Care
  8.3.5.5 Others
  8.3.6 Historic and Forecasted Market Size By End-User
  8.3.6.1 Hospitals & Clinics
  8.3.6.2 Research Laboratories
  8.3.6.3 Academic Institutions
  8.3.6.4 Biopharmaceutical Companies
  8.3.7 Historic and Forecast Market Size by Country
  8.3.7.1 Bulgaria
  8.3.7.2 The Czech Republic
  8.3.7.3 Hungary
  8.3.7.4 Poland
  8.3.7.5 Romania
  8.3.7.6 Rest of Eastern Europe
 8.4. Western Europe Plasma Fractionation Market
  8.4.1 Key Market Trends, Growth Factors and Opportunities
  8.4.2 Top Key Companies
  8.4.3 Historic and Forecasted Market Size by Segments
  8.4.4 Historic and Forecasted Market Size By Product Type
  8.4.4.1 Immunoglobulins
  8.4.4.2 Coagulation Factor Concentrates
  8.4.4.3 Albumi
  8.4.4.4 Protease Inhibitors
  8.4.4.5 Others
  8.4.5 Historic and Forecasted Market Size By Application
  8.4.5.1 Neurology
  8.4.5.2 Immunology
  8.4.5.3 Hematology
  8.4.5.4 Critical Care
  8.4.5.5 Others
  8.4.6 Historic and Forecasted Market Size By End-User
  8.4.6.1 Hospitals & Clinics
  8.4.6.2 Research Laboratories
  8.4.6.3 Academic Institutions
  8.4.6.4 Biopharmaceutical Companies
  8.4.7 Historic and Forecast Market Size by Country
  8.4.7.1 Germany
  8.4.7.2 UK
  8.4.7.3 France
  8.4.7.4 Netherlands
  8.4.7.5 Italy
  8.4.7.6 Russia
  8.4.7.7 Spain
  8.4.7.8 Rest of Western Europe
 8.5. Asia Pacific Plasma Fractionation Market
  8.5.1 Key Market Trends, Growth Factors and Opportunities
  8.5.2 Top Key Companies
  8.5.3 Historic and Forecasted Market Size by Segments
  8.5.4 Historic and Forecasted Market Size By Product Type
  8.5.4.1 Immunoglobulins
  8.5.4.2 Coagulation Factor Concentrates
  8.5.4.3 Albumi
  8.5.4.4 Protease Inhibitors
  8.5.4.5 Others
  8.5.5 Historic and Forecasted Market Size By Application
  8.5.5.1 Neurology
  8.5.5.2 Immunology
  8.5.5.3 Hematology
  8.5.5.4 Critical Care
  8.5.5.5 Others
  8.5.6 Historic and Forecasted Market Size By End-User
  8.5.6.1 Hospitals & Clinics
  8.5.6.2 Research Laboratories
  8.5.6.3 Academic Institutions
  8.5.6.4 Biopharmaceutical Companies
  8.5.7 Historic and Forecast Market Size by Country
  8.5.7.1 China
  8.5.7.2 India
  8.5.7.3 Japan
  8.5.7.4 South Korea
  8.5.7.5 Malaysia
  8.5.7.6 Thailand
  8.5.7.7 Vietnam
  8.5.7.8 The Philippines
  8.5.7.9 Australia
  8.5.7.10 New Zealand
  8.5.7.11 Rest of APAC
 8.6. Middle East & Africa Plasma Fractionation Market
  8.6.1 Key Market Trends, Growth Factors and Opportunities
  8.6.2 Top Key Companies
  8.6.3 Historic and Forecasted Market Size by Segments
  8.6.4 Historic and Forecasted Market Size By Product Type
  8.6.4.1 Immunoglobulins
  8.6.4.2 Coagulation Factor Concentrates
  8.6.4.3 Albumi
  8.6.4.4 Protease Inhibitors
  8.6.4.5 Others
  8.6.5 Historic and Forecasted Market Size By Application
  8.6.5.1 Neurology
  8.6.5.2 Immunology
  8.6.5.3 Hematology
  8.6.5.4 Critical Care
  8.6.5.5 Others
  8.6.6 Historic and Forecasted Market Size By End-User
  8.6.6.1 Hospitals & Clinics
  8.6.6.2 Research Laboratories
  8.6.6.3 Academic Institutions
  8.6.6.4 Biopharmaceutical Companies
  8.6.7 Historic and Forecast Market Size by Country
  8.6.7.1 Turkey
  8.6.7.2 Bahrain
  8.6.7.3 Kuwait
  8.6.7.4 Saudi Arabia
  8.6.7.5 Qatar
  8.6.7.6 UAE
  8.6.7.7 Israel
  8.6.7.8 South Africa
 8.7. South America Plasma Fractionation Market
  8.7.1 Key Market Trends, Growth Factors and Opportunities
  8.7.2 Top Key Companies
  8.7.3 Historic and Forecasted Market Size by Segments
  8.7.4 Historic and Forecasted Market Size By Product Type
  8.7.4.1 Immunoglobulins
  8.7.4.2 Coagulation Factor Concentrates
  8.7.4.3 Albumi
  8.7.4.4 Protease Inhibitors
  8.7.4.5 Others
  8.7.5 Historic and Forecasted Market Size By Application
  8.7.5.1 Neurology
  8.7.5.2 Immunology
  8.7.5.3 Hematology
  8.7.5.4 Critical Care
  8.7.5.5 Others
  8.7.6 Historic and Forecasted Market Size By End-User
  8.7.6.1 Hospitals & Clinics
  8.7.6.2 Research Laboratories
  8.7.6.3 Academic Institutions
  8.7.6.4 Biopharmaceutical Companies
  8.7.7 Historic and Forecast Market Size by Country
  8.7.7.1 Brazil
  8.7.7.2 Argentina
  8.7.7.3 Rest of SA

Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies

Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research